Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering.

It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

The company's development portfolio includes central nervous system (CNS), rare disease, immunology, and infectious disease product candidates.

Its CNS development portfolio include TNX-102 SL, which has completed two positive Phase 3 studies for the management of fibromyalgia, as well as being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition; and TNX-1300, a biologic designed to treat cocaine intoxication.

The company's rare disease development portfolio comprise TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS).

Its immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases.

The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox.

TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, in development as a vaccine to protect against COVID-19.

Its infectious disease development portfolio also comprises TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals.

The company was founded in 2007 and is headquartered in Chatham, New Jersey.